Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding.
Alexander T CohenMegan LewisAugusta ConnorStuart J ConnollyPatrick YueJohn CurnutteRaza AlikhanPeter MacCallumJoachim TanLaura GreenPublished in: Journal of the American College of Emergency Physicians open (2022)
In this propensity score-matched comparison across 2 independent datasets, adjusted 30-day mortality rates were lower for patients treated with andexanet alfa than in matched patients receiving PCC. This indirect comparison was limited in that it could not account for several highly predictive variables including GCS score, hematoma volume, and expected survival. Further research is warranted to confirm the mortality differences between reversal/replacement agents for DOAC-related bleeding.